1. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks.
- Author
-
Kang S, Leyden JJ, Lowe NJ, Ortonne JP, Phillips TJ, Weinstein GD, Bhawan J, Lew-Kaya DA, Matsumoto RM, Sefton J, Walker PS, and Gibson JR
- Subjects
- Administration, Cutaneous, Adult, Dermatologic Agents administration & dosage, Dermatologic Agents blood, Dermatologic Agents pharmacokinetics, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Face, Female, Humans, Hyperpigmentation pathology, Male, Nicotinic Acids administration & dosage, Nicotinic Acids blood, Nicotinic Acids pharmacokinetics, Prospective Studies, Retinoids administration & dosage, Retinoids blood, Retinoids pharmacokinetics, Treatment Outcome, Tretinoin administration & dosage, Tretinoin therapeutic use, United States, Dermatologic Agents therapeutic use, Hyperpigmentation drug therapy, Nicotinic Acids therapeutic use, Retinoids therapeutic use, Skin Aging pathology
- Abstract
Objective: To assess the safety and efficacy of 4 concentrations of tazarotene cream in the treatment of facial photodamage., Design: Prospective weekly multicenter, investigator-masked, randomized, parallel-group study., Setting: University hospitals and clinical research centers., Patients: Three hundred forty-nine subjects with facial photodamage., Intervention: Daily topical application of tazarotene cream (0.01%, 0.025%, 0.05%, and 0.1%) compared with its vehicle and with 0.05% tretinoin emollient cream., Results: Tazarotene cream and tretinoin cream significantly improved mottled hyperpigmentation and fine wrinkles. At week 24, treatment success rates based on global responses were 67% (39 of 58 subjects) with 0.1% tazarotene, 52% (30 of 58 subjects) with 0.05% tazarotene, 36% (21 of 58 subjects) with 0.025% tazarotene, 41% (24 of 59 subjects) with 0.01% tazarotene, 55% (32 of 58 subjects) with 0.05% tretinoin, and 22% (13 of 58 subjects) with vehicle. Local adverse events, although more frequent with tazarotene at higher concentrations, were generally mild to moderate., Conclusions: Tazarotene in a cream formulation is safe and is associated with positive changes in the treatment of photodamaged facial skin.
- Published
- 2001
- Full Text
- View/download PDF